2.20Open2.20Pre Close0 Volume1 Open Interest18.00Strike Price0.00Turnover2764.93%IV308.08%PremiumNov 15, 2024Expiry Date0.00Intrinsic Value100Multiplier2DDays to Expiry2.20Extrinsic Value100Contract SizeAmericanOptions Type0.6282Delta0.0388Gamma2.25Leverage Ratio-1.2333Theta0.0000Rho1.41Eff Leverage0.0013Vega
Inovio Pharmaceuticals Stock Discussion
Inovio Announces New Data at Scientific Conferences for Lead Candidate, Ino-3107, as a Potential Treatment for Rrp
On Friday, the fear of human-to-human spread grew ever so slightly: The CDC confirmed that four health-care workers in Missouri had fallen sick after caring for a patient who was infected with bird flu.
https://www.msn.com/en-us/health/other/bird-flu-pandemic-fears-skyrocket-as-us-identifies-first-cases-of-possible-human-to-human-transmission/ar-AA1rwhf5?ocid=BingNewsSerp
Inovio Receives Advanced Therapy Medicinal Product Certificate From European Medicines Agency for Quality and Non-Clinical Data for Lead Candidate Ino-3107
• BLA submission on track for INO-3107 in second half of 2024; if approved under accelerated approval pathway, could be first non-surgicaltreatment for recurrent respiratory papillomatosis (RRP)
• Planning initiation of confirmatory trial for INO-3107 based on FDA feedback
• Advancing plans for Phase 3 trial of INO-3112 in combination with LOQTORZITM ...
No comment yet